Clareo Health | Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Participant must be ≥ 18 at the time of signing the informed consent.
Histologically documented diagnosis of prostate adenocarcinoma that is de novo or recurrent and hormone-sensitive.
Metastatic disease confirmed prior to initiation of previous treatment with docetaxel or Lu-PSMA-containing regimens for mHSPC.
Previous treatment with docetaxel (IV, Q3w)- or Lu-PSMA (IV, Q6w) with last dose within past 6 months.
Participants must have the following:
* Must be receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy.
* Had no evidence of disease progression
* Had all toxicities related to docetaxel- or Lu-PSMA-containing treatment (except for alopecia and peripheral neuropathy) resolved to CTCAE Grade 1 or lower.
PSA ≥ 0.2 ng/mL within 14 days prior to randomization.
Serum testosterone \< 1.7 nmol/L or 50 ng/dL.
Palliative radiotherapy for symptoms management will be permitted and is to be completed at least 4 weeks prior to randomization for wide field radiation therapy and at least 2 weeks prior to randomization for limited field radiation therapy.
Provision of a FFPE tumor tissue sample and a blood sample (for ctDNA).
Confirmed HRRm, HRD and PTEN status.
Adequate organ and bone marrow function.
Minimum life expectancy of 6 months.
Male, assigned at birth, inclusive of all gender identities.
Contraceptive use by participants or participant partners should be consistent with local regulations.
Capable of giving signed informed consent.
\- -
You may not be if
Hypersensitivity to saruparib, ARPI or any excipients of these products or any contraindication or restriction based on the local label.
Any history of persisting (\> 2 weeks) severe cytopenia due to any cause (eg, ANC\< 0.5 × 10\^9/L or platelets \< 50 × 10\^9/L)
Any known predisposition to bleeding (eg, active peptic ulceration, recent \[within6 months\] hemorrhagic stroke, proliferative diabetic retinopathy.
Spinal cord compression or brain metastases unless asymptomatic and stable.
History of MDS/AML or with features suggestive of MDS/AML
History of another primary malignancy, with some exceptions.
Any chronic gastrointestinal diseases or conditions including inability to swallow the formulated product that would preclude adequate absorption of any study drug.
History of seizure or predispose to seizure, including any history of loss of consciousness or transient ischemic attack within 12 months of enrolment.
Serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
Major surgical procedure or significant traumatic injury within 4 weeks of the first dose or an anticipated need for major surgery during the study.
Switched ARPI agent in previous treatment for mHSPC due to disease progression. Note: if the ARPI agent was switched due to any reason other than disease progression and switch was prior to ICF signature, participants will be eligible.
Any prior treatment with a PARPi or platinum chemotherapy.
